Company Theriva Biologics, Inc.

Equities

TOVX

US87164U4094

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nyse Other stock markets 16:00:00 2024-05-16 EDT			5-day change	1st Jan Change
0.374 ^USD	+0.81%		-7.43%	-13.04%

05-07	Theriva Biologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-23	Theriva Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma	CI

Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment. SYN-004 (ribaxamase) is designed to degrade certain commonly used intravenous beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage. SYN-020 is a recombinant oral formulation of the enzyme intestinal alkaline phosphatase produced under current good manufacturing practice conditions and intended to treat both local GI and systemic diseases. Its research programs include VCN-11 Albumin Shield Technology and SYN-006, SYN-007, other oncolytic virus.

Number of employees: 22

Managers	Title	Age	Since
Steven Shallcross CEO	Chief Executive Officer	62	15-05-31
Michael Kaleko CTO	Chief Tech/Sci/R&D Officer	-	12-02-29
Ramon Alemany		-	-
T. J. Swope SEC	Corporate Secretary	-	-
Manel Cascalló PRN	Corporate Officer/Principal	-	22-03-22
Vince Wacher PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
Jeff Wolf BRD	Director/Board Member	60	05-12-31
John Monahan BRD	Director/Board Member	77	20-11-10
Jeffrey Kraws CHM	Chairman	59	05-12-31
Steven Shallcross CEO	Chief Executive Officer	62	15-05-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	17,997,604	16,946,072 ( 94.16 %)	720,233 ( 4.002 %)	94.16 %

Name	Equities	%	Valuation
Steven Shallcross 1.668 %	286,111	1.668 %	117 306 $
Vanguard Group, Inc. (Subfiler) 1.314 %	225,271	1.314 %	92 361 $
BlackRock Institutional Trust Co. NA 1.103 %	189,181	1.103 %	77 564 $
Geode Capital Management LLC 0.8232 %	141,168	0.8232 %	57 879 $
Frank Tufaro 0.4703 %	80,645	0.4703 %	33 064 $
Renaissance Technologies LLC 0.3995 %	68,510	0.3995 %	28 089 $
STATE STREET CORPORATION 0.2839 %	48,691	0.2839 %	19 963 $
Jane Street Group LLC 0.2773 %	47,559	0.2773 %	19 499 $
Virtu Financial LLC 0.2281 %	39,121	0.2281 %	16 040 $
Northern Trust Investments, Inc.(Investment Management) 0.1551 %	26,599	0.1551 %	10 906 $

Theriva Biologics, Inc.

9605 Medical Center Drive Suite 270

20850, Rockville

+301 417 4364

http://www.therivabio.com

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.374 USD

Average target price

2 USD

Spread / Average Target

+434.76%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
THERIVA BIOLOGICS, INC.	-13.04%	6.41M
VERTEX PHARMACEUTICALS INCORPORATED	+8.29%	114B
REGENERON PHARMACEUTICALS, INC.	+10.21%	104B
BIONTECH SE	-11.90%	22.41B
ARGENX SE	+0.20%	22.28B
GENMAB A/S	-5.66%	19.07B
WUXI APPTEC CO., LTD.	-37.36%	18B
BEIGENE, LTD.	-5.17%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.70%	14.28B
SAREPTA THERAPEUTICS, INC.	+37.65%	12.55B

Bio Therapeutic Drugs